These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 12511770)

  • 21. Expression of cyclooxygenase-2 mRNA after global ischemia is regulated by AMPA receptors and glucocorticoids.
    Koistinaho J; Koponen S; Chan PH
    Stroke; 1999 Sep; 30(9):1900-5; discussion 1905-6. PubMed ID: 10471443
    [TBL] [Abstract][Full Text] [Related]  

  • 22. NMDA and non-NMDA receptor gene expression following global brain ischemia in rats: effect of NMDA and non-NMDA receptor antagonists.
    Pellegrini-Giampietro DE; Pulsinelli WA; Zukin RS
    J Neurochem; 1994 Mar; 62(3):1067-73. PubMed ID: 8113793
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Delayed treatment with YM90K, an AMPA receptor antagonist, protects against ischaemic damage after middle cerebral artery occlusion in rats.
    Kawasaki-Yatsugi S; Shimizu-Sasamata M; Yatsugi S; Yamaguchi T
    J Pharm Pharmacol; 1998 Aug; 50(8):891-8. PubMed ID: 9751454
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reduction of cerebral infarct size by non-competitive AMPA antagonists in rats subjected to permanent and transient focal ischemia.
    Matucz E; Móricz K; Gigler G; Simó A; Barkóczy J; Lévay G; Hársing LG; Szénási G
    Brain Res; 2004 Sep; 1019(1-2):210-6. PubMed ID: 15306255
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The neuroprotective and hypothermic effect of GYKI-52466, a non-competitive alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid-antagonist on histological and behavioural variables in the gerbil global ischemia model.
    Gyertyán I; Gigler G; Simó A
    Brain Res Bull; 1999 Oct; 50(3):179-86. PubMed ID: 10566979
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthesis of 1,4,7,8,9,10-hexahydro-9-methyl-6-nitropyrido[3,4-f]- quinoxaline-2,3-dione and related quinoxalinediones: characterization of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (and N-methyl-D-aspartate) receptor and anticonvulsant activity.
    Bigge CF; Malone TC; Boxer PA; Nelson CB; Ortwine DF; Schelkun RM; Retz DM; Lescosky LJ; Borosky SA; Vartanian MG
    J Med Chem; 1995 Sep; 38(19):3720-40. PubMed ID: 7562904
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of decahydroisoquinoline-3-carboxylic acid monohydrate, a novel AMPA receptor antagonist, on glutamate-induced CA2+ responses and neurotoxicity in rat cortical and cerebellar granule neurons.
    Liljequist S; Cebers G; Kalda A
    Biochem Pharmacol; 1995 Nov; 50(11):1761-74. PubMed ID: 8615854
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Atropisomeric quinazolin-4-one derivatives are potent noncompetitive alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonists.
    Welch WM; Ewing FE; Huang J; Menniti FS; Pagnozzi MJ; Kelly K; Seymour PA; Guanowsky V; Guhan S; Guinn MR; Critchett D; Lazzaro J; Ganong AH; DeVries KM; Staigers TL; Chenard BL
    Bioorg Med Chem Lett; 2001 Jan; 11(2):177-81. PubMed ID: 11206453
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The search for selective blockers of NMDA and AMPA/kainate receptors in a series of bis-ammonium compounds with adamantyl radicals].
    Gmiro VE; Serdiuk SE
    Eksp Klin Farmakol; 2000; 63(1):7-13. PubMed ID: 10763102
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reevaluation of ACEA 1021 as an antagonist at the strychnine-insensitive glycine site of the N-methyl-D-aspartate receptor.
    Lingenhöhl K; Pozza MF
    Neuropharmacology; 1998 Jun; 37(6):729-37. PubMed ID: 9707286
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterization of the binding site for a novel class of noncompetitive alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonists.
    Menniti FS; Chenard BL; Collins MB; Ducat MF; Elliott ML; Ewing FE; Huang JI; Kelly KA; Lazzaro JT; Pagnozzi MJ; Weeks JL; Welch WM; White WF
    Mol Pharmacol; 2000 Dec; 58(6):1310-7. PubMed ID: 11093768
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neuroprotective efficacy of YM872, an alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor antagonist, after permanent middle cerebral artery occlusion in rats.
    Takahashi M; Ni JW; Kawasaki-Yatsugi S; Toya T; Ichiki C; Yatsugi SI; Koshiya K; Shimizu-Sasamata M; Yamaguchi T
    J Pharmacol Exp Ther; 1998 Nov; 287(2):559-66. PubMed ID: 9808681
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neuroprotective cannabinoid receptor antagonist SR141716A prevents downregulation of excitotoxic NMDA receptors in the ischemic penumbra.
    Sommer C; Schomacher M; Berger C; Kuhnert K; Müller HD; Schwab S; Schäbitz WR
    Acta Neuropathol; 2006 Sep; 112(3):277-86. PubMed ID: 16871404
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is pharmacological neuroprotection dependent on reduced glutamate release?
    Calabresi P; Picconi B; Saulle E; Centonze D; Hainsworth AH; Bernardi G
    Stroke; 2000 Mar; 31(3):766-72; discussion 773. PubMed ID: 10700517
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neuroprotective effect of a novel AMPA receptor antagonist, YM90K, in rat focal cerebral ischaemia.
    Umemura K; Shimakura A; Nakashima M
    Brain Res; 1997 Oct; 773(1-2):61-5. PubMed ID: 9409705
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differential antagonism of alpha-amino-3-hydroxy-5-methyl-4- isoxazolepropionic acid-preferring and kainate-preferring receptors by 2,3-benzodiazepines.
    Wilding TJ; Huettner JE
    Mol Pharmacol; 1995 Mar; 47(3):582-7. PubMed ID: 7700255
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A dose-response study of neuroprotection using the AMPA antagonist NBQX in rat focal cerebral ischemia.
    Graham SH; Chen J; Lan JQ; Simon RP
    J Pharmacol Exp Ther; 1996 Jan; 276(1):1-4. PubMed ID: 8558416
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pentylenetetrazole-induced seizures affect binding site densities for GABA, glutamate and adenosine receptors in the rat brain.
    Cremer CM; Palomero-Gallagher N; Bidmon HJ; Schleicher A; Speckmann EJ; Zilles K
    Neuroscience; 2009 Sep; 163(1):490-9. PubMed ID: 19345722
    [TBL] [Abstract][Full Text] [Related]  

  • 39. YM872, a highly water-soluble AMPA receptor antagonist, preserves the hemodynamic penumbra and reduces brain injury after permanent focal ischemia in rats.
    Shimizu-Sasamata M; Kano T; Rogowska J; Wolf GL; Moskowitz MA; Lo EH
    Stroke; 1998 Oct; 29(10):2141-8. PubMed ID: 9756596
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Stereoselective neuroprotection by novel 2,3-benzodiazepine non-competitive AMPA antagonist against non-NMDA receptor-mediated excitotoxicity in primary rat hippocampal cultures.
    May PC; Robison PM; Fuson KS
    Neurosci Lett; 1999 Mar; 262(3):219-21. PubMed ID: 10218895
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.